Welcome to our dedicated page for Biocryst Pharmaceuticals SEC filings (Ticker: BCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its operations as a biotechnology company focused on hereditary angioedema (HAE) and other rare diseases. On this page, you can review BioCryst’s SEC filings alongside AI-generated summaries that help explain complex disclosures in clear language.
Current Reports on Form 8-K are especially important for tracking material events at BioCryst. Recent 8-K filings describe key regulatory milestones, such as U.S. Food and Drug Administration approval of the New Drug Application for an oral pellet formulation of once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric HAE patients aged 2 to <12 years. Other 8-Ks cover quarterly financial results, preliminary revenue updates, and guidance for ORLADEYO net revenue, total revenue including RAPIVAB® (peramivir injection), and non-GAAP operating expenses.
Filings also document strategic transactions that shape BioCryst’s business model. One set of 8-Ks details the Stock Purchase Agreement and subsequent closing of the sale of BioCryst Ireland Limited, which held certain assets and rights related to the European ORLADEYO business, along with associated IP license, supply, brand support, transition services, and trademark license agreements. Another 8-K outlines the Agreement and Plan of Merger under which a BioCryst subsidiary will merge with Astria Therapeutics, Inc., including the cash-and-stock merger consideration, closing conditions, and potential delisting of Astria’s stock.
Governance and compensation developments also appear in BioCryst’s filings. Recent 8-Ks describe the planned retirement of the company’s President and Chief Executive Officer, the appointment of a new President and future CEO, the hiring of a new Chief Financial Officer, and related employment and separation agreements. Additional filings report inducement equity grants to new employees in accordance with Nasdaq Listing Rule 5635(c)(4).
Alongside these 8-Ks, investors can use this page to access BioCryst’s periodic reports on Forms 10-K and 10-Q (when available), which provide detailed discussions of risk factors, business strategy, and financial statements. Stock Titan’s AI tools highlight key sections of lengthy documents such as annual reports (10-K), quarterly reports (10-Q), and insider transaction filings (Form 4), helping you quickly understand revenue drivers, major agreements, executive changes, and other disclosures that may affect BCRX.
BioCryst Pharmaceuticals entered a European license agreement granting an Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart for hereditary angioedema. BioCryst will receive $70 million upfront, up to $275 million in future regulatory and sales milestone payments, plus tiered royalties on net sales ranging from 18% to 30%.
Navenibart is an investigational, long-acting plasma kallikrein inhibitor currently in a Phase 3 program in hereditary angioedema, with the program described as on track to support a US regulatory filing by the end of 2027. The company highlights that the deal strengthens its financial position while leveraging Neopharmed Gentili’s existing European rare disease infrastructure.
BioCryst Pharmaceuticals Inc reports that Vanguard Capital Management beneficially owns 12,961,172 shares of Common Stock as of 03/31/2026, representing 5.16% of the class.
The filing lists sole voting power of 1,825,410 shares and sole dispositive power over 12,961,172 shares. The Schedule 13G was signed by Ashley Grim on 04/29/2026.
BioCryst Pharmaceuticals is holding its 2026 annual stockholder meeting on June 11, 2026 to vote on key governance and compensation matters. Stockholders will elect three directors for terms ending in 2029, ratify Ernst & Young LLP as auditor for 2026, and cast an advisory vote on executive pay.
A major proposal seeks approval of an amended and restated Stock Incentive Plan adding 7,000,000 shares. As of April 13, 2026, 54,027,003 shares were reserved or available under the plan, with 254,105,895 common shares outstanding, implying potential dilution of 2.8%. The company argues the increase is needed to attract and retain talent, support ORLADEYO commercialization and pipeline programs, and maintain a broad-based equity culture. The plan includes shareholder-friendly terms such as no repricing without approval, a minimum one-year vesting rule (with limited exceptions), caps on director compensation, no evergreen feature, and double-trigger change-of-control vesting.
BioCryst Pharmaceuticals Chief R&D Officer Sandeep Menon received equity grants as part of his compensation. On April 6, 2026, he was granted 441,350 employee stock options for common stock at an exercise price of $9.47 per share, expiring in 2036.
He also received an inducement grant of 205,150 restricted stock units of common stock. Both the RSUs and the options vest or become exercisable in equal 25% installments on each of the first, second, third and fourth anniversaries of the grant date, aligning his incentives with longer-term company performance rather than reflecting open-market trading.
BIOCRYST PHARMACEUTICALS INC filed an initial Form 3 for Chief R&D Officer Sandeep Menon. This document establishes his status as a reporting insider at the company. The filing does not list any transactions, so it serves mainly as a baseline disclosure of his insider reporting obligations.
BioCryst Pharmaceuticals disclosure: The Vanguard Group filed an amendment to its Schedule 13G reporting 0 shares beneficially owned, representing 0% of Common Stock as of the amendment. The filing explains an internal realignment that disaggregated certain Vanguard subsidiaries' reporting of holdings.
BIOCRYST PHARMACEUTICALS INC director Theresa Heggie exercised stock options and sold shares on March 20, 2026. She exercised options for 49,933 shares of Common Stock at an exercise price of $6.30 per share and acquired the same number of shares.
She then sold 49,933 Common shares in an open-market transaction at a weighted average price of $10.11 per share, in multiple trades between $10.09 and $10.14. Following these transactions, she directly holds 65,352 shares of Common Stock.
BioCryst Pharmaceuticals Chief Legal Officer Alane P. Barnes exercised stock options and sold shares in a planned transaction. On March 16, 2026, she exercised options for 150,000 shares of common stock at an exercise price of $5.51 per share.
The same day, she sold 150,000 shares of common stock at a weighted average price of $9.15 per share, with individual sale prices ranging from $8.95 to $9.57. After these transactions, she directly owned 400,703 shares of common stock. The filing states the sale was made automatically under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2025, indicating it was not a discretionary trade.